TCR2 THERAPEUTICS INC. Quarterly Depreciation in USD from Q1 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Tcr2 Therapeutics Inc. quarterly/annual Depreciation history and growth rate from Q1 2018 to Q1 2023.
  • Tcr2 Therapeutics Inc. Depreciation for the quarter ending March 31, 2023 was $500K, a 16.7% decline year-over-year.
  • Tcr2 Therapeutics Inc. annual Depreciation for 2022 was $2.65M, a 6.44% decline from 2021.
  • Tcr2 Therapeutics Inc. annual Depreciation for 2021 was $2.83M, a 77.6% increase from 2020.
  • Tcr2 Therapeutics Inc. annual Depreciation for 2020 was $1.59M, a 84.7% increase from 2019.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $500K -$100K -16.7% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q1 2022 $600K +$87K +17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $513K +$207K +67.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $430K +$172K +66.7% Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-12
Q1 2020 $1.03M $306K +$171K +127% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $862K $304K +$188K +162% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $674K $258K +$143K +124% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $531K $165K +$53K +47.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $478K $135K +$59K +77.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $419K $116K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 $115K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $112K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $76K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.